By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
Great summary David on a cool abstract by Kevin Winthrop- unfortunately we still lack any predictive biomarker of clinical protection from VZV - so though intriguing we desperately need clinical vaccine studies in OUR patients. Lastly I am not impressed/concerned about Ab responses since there is virtually no data on their protective effect here. Hypogamma pts do quite well w VZV risks.- CME is where is where its at ..............